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Allogeneic hematopoietic cell transplantation (HCT) can cure some chronic lymphocytic leukemia (CLL)
subjects. This study compared outcomes of myeloablative (MA) and reduced-intensity conditioning (RIC)
transplants from HLA-matched sibling donors (MSD) for CLL. From 1995 to 2007, information regarding 297
CLL subjects was reported to the Center of International Blood and Marrow Transplant Research; of these, 163
underwent MA and 134 underwent RIC MSD HCT. The MA subjects underwent transplantation less often after
2000 and less commonly received antithymocyte globulin (4% versus 13%, P ¼ .004) or prior antibody therapy
(14% versus 53%; P < .001). RIC was associated with a greater likelihood of platelet recovery and less grade 2 to
4 acute graft-versus-host disease compared with MA conditioning. One- and 5-year treatment-related
mortality (TRM) were 24% (95% conﬁdence intervals [CI], 16% to 33%) versus 37% (95% CI, 30% to 45%; P ¼
.023), and 40% (95% CI, 29% to 51%) versus 54% (95% CI, 46% to 62%; P ¼ .036), respectively, and the relapse/
progression rates at 1 and 5 years were 21% (95% CI, 14% to 29%) versus 10% (95% CI, 6% to 15%; P ¼ .020), and
35% (95% CI, 26% to 46%) versus 17% (95% CI, 12% to 24%; P ¼ .003), respectively. MA conditioning was
associated with better progression-free (PFS) (relative risk, .60; 95% CI, .37 to .97; P ¼ .038) and 3-year survival
in transplantations before 2001, but for subsequent years, RIC was associated with better PFS and survival
(relative risk, 1.49 [95% CI, .92 to 2.42]; P ¼ .10; and relative risk, 1.86 [95% CI, 1.11 to 3.13]; P ¼ .019).edgments on page 1397.
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R.M. Sobecks et al. / Biol Blood Marrow Transplant 20 (2014) 1390e1398 1391Pretransplantation disease status was the most important predictor of relapse (P ¼ .003) and PFS (P ¼ .0007)
for both forms of transplantation conditioning. MA and RIC MSD transplantations are effective for CLL. Future
strategies to decrease TRM and reduce relapses are warranted.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION and graded using consensus criteria [18,19]. For hematopoietic recovery and
Myeloablative (MA) allogeneic hematopoietic cell trans-
plantations (HCT) in persons with advanced chronic lym-
phocytic leukemia (CLL) have relapse rates of 10% to 20%
[1-6]. However, treatment-related mortality (TRM) is 30%
to 40% [1,3,6,7]. Because the majority of patients with CLL are
older and have comorbidities, reduced-intensity condition-
ing (RIC) transplantations are an attractive option.
RIC allogeneic transplantations have successfully been
performed for CLL with durable long-term survival [8-14].
They are associated with less toxicity and less early TRM
compared with MA conditioning. RIC also can prevent
relapse in subjects with advanced CLL, with complete
response rates of 40% to 55% and progression-free survival
(PFS) of 40% [8,13-15].
RIC transplantations are increasingly used, but no large
series has compared outcomes with transplantations with
MA conditioning. We analyzed the outcomes of HLA-
matched sibling donor (MSD) RIC and MA conditioning ap-
proaches for persons with advanced CLL reported to the
Center of International Blood and Marrow Transplant
Research (CIBMTR).
PATIENTS AND METHODS
Data Sources
The CIBMTR is a combined research program of the Medical College of
Wisconsin and the National Marrow Donor Program. CIBMTR comprises a
voluntary network ofmore than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and autologous HCT to a
centralized Statistical Center. Observational studies conducted by CIBMTR
are performed in compliance with all applicable federal regulations per-
taining to the protection of human research participants. Protected health
information used in the performance of such research is collected and
maintained in CIBMTR’s capacity as a Public Health Authority under the
Health Insurance Portability and Accountability Act Privacy Rule. Additional
details regarding the data source are described elsewhere [16].
Subject Eligibility
Subjects 40 to 59 years old with advanced CLL receiving a ﬁrst HLA-MSD
transplantation between 1995 and 2007 were eligible for the study. This age
range was selected to make a more balanced comparison between the RIC
and MA cohorts. Of 1260 CLL subjects reported to the CIBMTR during this
time,163MA and 134 RIC HLA-MSD transplantations were reported. Data on
disease-speciﬁc variables were not collected on unrelated donor HCT during
study years; therefore, unrelated donor HCT recipients were excluded. Other
exclusions include twin transplantations, HLA-haploidentical and umbilical
cord blood transplantations, and those using ex vivo T celledepleted grafts.
No subjects received a prior autologous or allogeneic transplantation. The
respective 3- and 5-year follow-up completeness index for data reported to
the CIBMTR on study subjects were 86% and 76% [17].
Study Endpoints
Coprimary endpoints were PFS and survival. Secondary endpoints
included hematopoietic recovery, TRM, acute and chronic graft-versus-host
disease (GVHD), and relapse/progression. Survival was deﬁned as time to
death from any cause. Subjects were censored at time of last follow-up.
Relapse/progression was deﬁned as reported by the transplantation centers
and TRM was considered a competing event. TRM was deﬁned as death
within the ﬁrst 28 days of transplantation from any cause or death without
evidence of recurrence; relapse was considered a competing event. PFS was
deﬁned as time to treatment failure (death or relapse). For relapse, TRM, and
PFS, subjects alive in continuous complete remission were censored at last
follow-up. Hematopoietic recovery was deﬁned as time to absolute neutro-
phil count >.5  109/L for 3 consecutive days and time to platelets >
20  109/L without transfusions for 7 days, using the ﬁrst of 3 consecutive
results obtained on different days. Acute and chronic GVHD were diagnosedGVHD, death without the event was considered a competing event.
Rai stage was determined as previously described [20]. Fludarabine
failure was deﬁned as not meeting criteria for partial or complete response
after such therapy. The transplantation conditioning regimen intensity was
determined according to the CIBMTR RIC Regimen Workshop [21].
Statistical Analysis
PFS and survival curves were estimated by the Kaplan-Meier method
[22]. Patient-, disease-, and transplantation-related factors were compared
between groups using the Chi-square test for categorical variables and the
Wilcoxon 2-sample test for continuous variables. Cumulative incidence es-
timates to account for competing risks were calculated for hematopoietic
recovery, TRM, acute and chronic GVHD, and disease relapse/progression.
Cox proportional hazards regression was used to compare MA and RIC
regimens. The assumption of proportional hazards for each factor in the Cox
model was tested using time-dependent covariates. The multivariate model
was built using a stepwise model selection approach. The main effect vari-
able was MA versus RIC. The following variables were analyzed for their
prognostic value on each of the outcomes: patient characteristics (age, sex,
and Karnofsky performance status [KPS]), disease characteristics (Rai stage
at diagnosis and at transplantation, constitutional symptoms, lactate de-
hydrogenase at transplantation, spleen status, and disease status at trans-
plantation), and transplantation-related factors (time from diagnosis to HCT,
donor age, donor-recipient gender and cytomegalovirus serology, GVHD
prophylaxis regimen, and year of HCT). First order interactions between
main effect and signiﬁcant covariates were tested. In particular, because the
year of transplantationwas confoundedwith themain effect, the interaction
between them was checked for all endpoints. For survival and PFS, an
interaction between the main effect and year of HCT was found. The cut-off
for year of HCT was determined using the maximum partial likelihood
method. Factors signiﬁcantly associated with the outcome variable at a 5%
level were kept in the ﬁnal model. All P values were 2-sided.
RESULTS
Transplantation Subjects
Subject- and disease-related characteristics are shown in
Table 1. Subjects who received RIC transplantations were
older, but with comparable baseline KPS compared with
those who received MA regimens. The MA group less
commonly received prior antibody therapy (19 [14%] versus
40 [53%], P < .001). No differences were found between the
groups regarding disease that was refractory to ﬂudarabine
or antibody therapy before transplantation.
From the maximum partial likelihood method, a 2000
cut-off for year of HCT was chosen for subsequent analyses.
When considering patient- and disease-related characteris-
tics for those who underwent transplantation in 2000 or
earlier, the only differences between theMA and RIC subjects
were median age (49 years [range, 40 to 59 years] versus
53 years [40 to 59 years], P < .001), prior antibody therapy
(2% versus 25%, P < .001), graft source (blood: 47% versus
89%, P < .001), and median donor age (47 years [27 to
65 years] versus 52 years [37 to 65 years], P ¼ .006).
Compared with the MA subjects, the RIC group more
commonly received antithymocyte globulin (ATG) for con-
ditioning or GVHD prophylaxis (15% versus 2%, P ¼ .005) and
less commonly received methotrexate for GVHD prophylaxis
(26% versus 79%, P < .001).
For subjects who underwent transplantation after 2000,
the patient- and disease-related characteristics were com-
parable between the MA and RIC subjects, except for the
following respective differences: median age (51 years
[range, 40 to 59 years] versus 54 years [42 to 59 years],
P ¼ .005) and graft source (blood: 92% versus 99%, P ¼ .024).
Table 2
Transplantation-Related Characteristics for CLL Subjects Undergoing HLA-
Matched Sibling Donor MA and RIC Allogeneic HCT
Variable MA RIC P Value
Time from diagnosis to
transplantation,
median (range), mo
43 (2-223) 52 (5-184) .118
CD34þ cell dose, median
(range),106/kg
5 (1-31) 5 (1-43) .291
Missing 68 (42) 16 (12)
Conditioning regimens*,y <.001
MA e TBI-based 110 (67) 0
MA e chemotherapy-based 53 (33) 0
RIC e TBI-based 0 43 (32)
RIC e chemotherapy-based 0 83 (61)
Donor-recipient sex match .251
M-M 63 (39) 52 (39)
F-F 15 (9) 23 (17)
M-F 27 (17) 20 (15)
F-M 57 (35) 39 (29)
Missing 1 (<1) 0
Donor-recipient CMV match .325
D()/R() 42 (26) 29 (22)
D(þ)/R(þ) 74 (45) 51 (38)
D(þ)/R() 16 (10) 16 (12)
D()/R(þ) 26 (16) 33 (25)
Missing 5 (3) 5 (4)
Source of hematopoietic stem cells <.001
Bone marrow 69 (42) 4 (3)
Peripheral blood 94 (58) 130 (97)
Donor age, median (range), yr 47 (27-67) 50 (32-70) .002
Donor age at transplantation, yr .02
20-29 3 (2) 0
30-39 23 (14) 9 (7)
40-49 76 (47) 52 (39)
50-59 45 (28) 56 (42)
60-70 13 (8) 16 (12)
Missing 3 (2) 1 (<1)
ATG given for conditioning
or GVHD prophylaxis
.008
Yes 6 (4) 17 (13)
No 157 (96) 116 (87)
Missing 0 1 (<1)
GVHD prophylaxis <.001
Tac þ MTX þ/ otherz 20 (12) 26 (19)
Tac þ/ otherz 11 (7) 16 (12)
CsA þ MTX þ/ otherz 107 (66) 35 (26)
CsA þ/ otherz 18 (11) 53 (40)
Otherz 0 1 (<1)
Missing 7 (4) 3 (2)
Year of transplantation <.001
1995 29 (18) 0
1996 27 (17) 1 (<1)
1997 25 (15) 1 (<1)
1998 15 (9) 3 (2)
1999 18 (11) 4 (3)
2000 11 (7) 18 (13)
2001 5 (3) 18 (13)
2002 8 (5) 18 (13)
2003 5 (3) 15 (11)
2004 3 (2) 19 (14)
2005 7 (4) 17 (13)
2006 8 (5) 15 (11)
2007 2 (1) 5 (4)
Median follow-up of
survivors, range, mo
108 (3-175) 47 (3-143)
There were insufﬁcient data for the CD3þ cell dose to be used in the anal-
ysis.
TBI indicates total body irradiation; M, male; F, female; CMV, cytomegalo-
virus; Tac, tacrolimus; MTX, methotrexate; CsA, cyclosporine.
* TBIetotal body irradiation; there were an additional 8 RIC subjects
Table 1
Patient and Disease-Related Characteristics for CLL Subjects Undergoing
HLA- Matched Sibling Donor MA and RIC Allogeneic HCT
Variable MA RIC P Value
Patient related
Number of subjects 163 134
Number of centers 83 60
Age, median (range), yr 49 (40-59) 54 (40-59) <.001
Age at transplantation, yr <.001
40-49 88 (54) 33 (25)
50-59 75 (46) 101 (75)
Gender .280
Male 120 (74) 91 (68)
Female 43 (26) 43 (32)
Karnofsky score (before
transplantation)
.489
<90% 50 (31) 45 (34)
90% 110 (67) 84 (63)
Missing 3 (2) 5 (4)
Disease related
Rai stage at diagnosis .941
Early Rai stages 103 (63) 86 (64)
Late Rai stages 32 (20) 27 (20)
Missing 28 (17) 21 (16)
Rai stage before HCT .758
Early 92 (56) 70 (52)
Advanced 58 (36) 53 (40)
Missing 13 (8) 11 (8)
Elevated LDH at
transplantation
.871
No 84 (52) 65 (49)
Yes 51 (31) 45 (34)
Missing 28 (17) 24 (18)
Number of lines of
therapy received before
transplantation, median
(range)
3 (1-5) 3 (1-5) .856
Prior therapy received <.18*
Yes 139 (85) 76 (57)
Missing 24 (15) 58 (43)
Refractory to the last line
of therapy
.185y
Yes 44 (32) 18 (24)
No 91 (65) 58 (76)
Missing 4 (3) 0
Disease status at
transplantation
.091
CR/PR/nPR 72 (44) 73 (55)
Stable/progressive 81 (50) 58 (43)
Missing/untreated 10 (6) 3 (2)
Refractory to ﬂudarabine
at any time before
transplantationy
.192y
No 108 (66) 50 (37)
Yes 41 (25) 28 (21)
LDH indicates lactate dehydrogenase; CR, complete remission; PR, partial
remission; nPR, nodular partial remission.
* P values were calculated by excluding those with missing data.
y Fourteen MA and 56 RIC subjects were missing data regarding prior
ﬂudarabine failure to any line of therapy.
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istics to be used in the analysis: percent CLL in the bone
marrow before transplantation, lymphadenopathy (5 cm),
serum b-2 microglobulin level, immunophenotype, immu-
noglobulin gene rearrangement Ig mutation state, and cy-
togenetic abnormalities.including 7 who received total lymphoid irradiation and ATG, and 1 who
received thoracoabdominal irradiation and cyclophosphamide.
y Rituximab was included in the conditioning regimen for 1 MA and 10
RIC transplantations. alemtuzumab was included in the conditioning
regimen for 0 MA and 10 RIC transplantations.
z Other includes mycophenolate mofetil, monoclonal antibody, ursodiol,
and corticosteroids.Transplantation Regimens
Transplantation-related variables are presented in
Table 2. Most RIC subjects received a total body irradiation
(TBI)ebased or ﬂudarabinewith cyclophosphamide regimen,
Table 3
Post-transplantation Outcomes for CLL Subjects Undergoing MA and RIC
Allogeneic HCT
Outcomes MA RIC P Value
(Pointwise)
Probability
(95% CI)
Probability
(95% CI)
Acute GVHD (II-IV)
No. evaluable 162 132
At 100 days 49 (41-56) 35 (27-44) .017
Acute GVHD (III-IV)
No. evaluable 162 133
At 100 days 26 (20-33) 23 (16-30) .522
Chronic GVHD
No. evaluable 153 131
At 1 yr 41 (33-49) 35 (27-44) .360
At 3 yr 44 (36-52) 39 (30-48) .375
At 5 yr 44 (36-52) 39 (30-48) .375
Treatment related mortality - overall
No. evaluable 159 110
At 100 days 21 (15-27) 12 (7-19) .048
At 1 yr 37 (30-45) 24 (16-33) .023
At 3 yr 47 (39-55) 31 (22-40) .009
At 5 yr 54 (46-62) 40 (29-51) .036
Progression/relapse - overall
No. evaluable 159 110
At 1 yr 10 (6-15) 21 (14-29) .020
At 3 yr 14 (9-20) 32 (23-41) .002
At 5 yr 17 (12-24) 35 (26-46) .003
Progression-free survival: HCT  2000
No. evaluable 124 24 .031*
At 1 yr 55 (46-64) 33 (16-53) .039
At 3 yr 43 (35-52) 21 (7-39) .018
At 5 yr 31 (23-40) 10 (1-27) .011
Progression-free survival: HCT > 2000
No. evaluable 35 86 .086*
At 1 yr 44 (27-61) 62 (51-72) .080
At 3 yr 22 (10-37) 43 (31-54) .027
At 5 yr 22 (10-37) 30 (19-43) .387
Overall survival: HCT  2000
No. evaluable 125 27 .097*
At 1 yr 57 (48-66) 41 (23-59) .115
At 3 yr 46 (37-55) 26 (11-44) .034
At 5 yr 37 (28-46) 21 (7-39) .089
Overall survival: HCT > 2000
No. evaluable 38 107 .016*
At 1 yr 52 (35-68) 83 (75-90) <.001
At 3 yr 36 (21-53) 62 (52-72) .008
At 5 yr 36 (21-53) 48 (36-60) .255
Causes of death n ¼ 99
(61%)
n ¼ 74
(55%)
Relapsed/progressive CLL 27 32
Organ failure 19 6
GVHD 13 9
Infection 10 11
Hemorrhage 4 3
Sinusoidal obstruction syndrome 4 0
Acute respiratory distress syndrome 4 2
Secondary malignancy 2 1
Graft failure 1 0
Thromboembolic event 1 0
Idiopathic pneumonia 1 1
Unknown 13 9
* Log rank test.
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TBI-based or busulfanwith cyclophosphamide. Bonemarrow
was more commonly used as a graft for the MA group. ATG
was more often given with the transplantation conditioning
regimen or as GVHD prophylaxis among the RIC subjects
(13% versus 4%, P ¼ .004). This group also had an older me-
dian donor age. Most MA transplantations were done before
2000, whereas most RIC transplantations were done later.
Hematopoietic Recovery
Although rates of neutrophil recovery at days 28 and 100
were comparable between the groups, signiﬁcantly more RIC
subjects achieved platelet recovery at these time points (91%
[95% conﬁdence interval (CI), 86% to 96%] versus 60% [95% CI,
52% to 67%], P < .001; and 95% [95% CI, 90% to 98%] versus
82% [95% CI, 76% to 88%], P < .001, respectively).
Primary graft failure occurred in 3 subjects who received
MA conditioning and in 4 who underwent RIC HCT. Two
subjects in the MA group died within 60 days of trans-
plantation, but the other received a second graft.
GVHD
The cumulative incidence of grades2 to 4 acute GVHD at
day 100 was greater in the MA group (49% versus 35%, P ¼
.017), but there was no difference for grades 3 and 4 acute
GVHD (Table 3; Figure 1A,B). In multivariate analysis, MA
conditioning was associated with an 80% increased risk of 
grade 2 acute GVHD (Table 4).
The cumulative incidences of chronic GVHD at 1, 3, and
5 years were comparable between those receiving MA or RIC
regimens (Table 3, Figure 1C). In multivariate analysis, a
pretransplantation KPS < 90% was associated with more
chronic GVHD (Table 4).
Disease Relapse/Progression and Survival
Subjects in the MA group had signiﬁcantly lower inci-
dence of disease relapse/progression compared with RIC
subjects (Table 3, Figure 1D). In multivariate analysis, there
was a 55% reduction in risk of disease relapse with MA
conditioning (Table 4). Other signiﬁcant variables associated
with decreased relapse risk included a pretransplantation
KPS 90 and complete or partial remission disease status at
the time of transplantation.
When considering the MA and the RIC groups indepen-
dently, therewere no differences in the cumulative incidence
of disease progression/relapse at 1, 3, and 5 years after
transplantation for those who failed prior ﬂudarabine ther-
apy compared with the others (data not shown). When next
considering only subjects who failed prior ﬂudarabine, the
cumulative incidence of disease progression/relapse was
similar for those treated with RIC and those treated with MA
HCT at 1, 3, and 5 years after transplantation. Lastly, for those
subjects who were not ﬂudarabine failures, there were no
differences between the MA and RIC groups with regards to
disease progression/relapse.
TRM was signiﬁcantly higher at 100 days, 1 year, 3 years,
and 5 years after transplantation for those who received MA
conditioning (Table 3, Figure 1E). Inmultivariate analysis, MA
conditioning was associated with a 40% increased risk of
TRM compared with RIC, but this increase in risk did not
reach statistical signiﬁcance (Table 4).
We observed an interaction between the main effect and
year of transplantation for the PFS outcome. Assessment of
subjects who underwent transplantation before 2001
showed better PFS for the MA group, as conﬁrmed inmultivariate analysis (P ¼ .038) (Tables 3 and 4; Figure 2A).
However, after 2000, the 1- and 3-year PFS were better for
those who received RIC transplantations (Table 3, Figure 2B).
In multivariate analysis, RIC was associated with a trend to-
wards improved PFS, but it did not reach statistical signiﬁ-
cance (Table 4). Pretransplantation disease status was the
most important predictor of PFS (P¼ .0007) and KPS was also
associated with improved PFS.
Median follow-up of survivors in the MA and RIC groups
was 129 months (range, 3 to 175 months) and 113 months
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Figure 1. Cumulative incidence curves comparing (A) grades II to IV and (B) grades III to IV acute GVHD, (C) chronic GVHD, (D) progression/relapse, and (E) TRM
between MA and RIC allogeneic HCT for CLL.
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interaction between the main effect and year of trans-
plantation. For those who underwent transplantation in
2000 or earlier, only the 3-year survival was signiﬁcantly
better with MA conditioning compared with RIC (Table 3,
Figure 3A). However, in subjects who underwent trans-
plantation after 2000, MA conditioning was associated with
signiﬁcantly worse 1- and 3-year survival. This was
conﬁrmed in multivariate analysis (P ¼ .019) (Tables 3 and 4;
Figure 3B). At 1, 2, and 5 years after transplantation, there
were 79, 64, and 31 MA patients alive with 10, 8, and 0 re-
lapses, respectively, and 50, 32, and 11 RIC patients alivewith
11, 3, and 0 relapses, respectively. A landmark analysisperformed among patients alive and disease-free at 1 year
after transplantation was undertaken to evaluate late
relapse, which was signiﬁcantly less for the MA group
(relative risk, .32; 95% CI, .13 to .78; P ¼ .013). For subjects
who had disease relapse after transplantation, the 1-year
survival from the time of HCT for the MA and RIC groups
was 58% and 77%, respectively (P ¼ .07).
When considering the MA and the RIC groups indepen-
dently, there were no differences in survival when
comparing those with or without prior ﬂudarabine failure.
For those who failed any line of pretransplantation ﬂudar-
abine therapy, survival also did not differ between MA and
RIC subjects. However, among all other subjects who did not
Table 4
Multivariate Analysis Results for CLL Subjects Undergoing MA and RIC
Allogeneic HCT
RR (95% CI) P Value N
1. Overall Survival
Main effect and transplantation
year
2000 or earlier
RIC 1 .14* 27
MA .70 (.44-1.12) .14 122
After 2000
RIC 1 .019* 102
MA 1.87 (1.11-3.13) .019 38
Rai stage immediately before HCT
Early 1 .014* 159
Advanced 1.60 (1.16-2.19) .0039 106
Missing 1.41 (.80-2.50) .23 24
Contrast
Advanced versus missing 1.13 (.63-2.01) .68
2. Acute GVHD II-IV
Main effect
RIC 1 .0017* 129
MA 1.80 (1.25-2.59) .0017 160
3. Chronic GVHD
Main effect
RIC 1 .079* 129
MA 1.42 (.96-2.10) .079 160
Karnofsky performance status
90 1 .023* 95
<90 1.58 (1.07-2.34) .023 194
4. Relapse
Main effect
RIC 1 .004* 108
MA .46 (.27-.78) .004 156
Karnofsky performance status
90 1 .007* 84
<90 2.06 (1.22-3.49) .007 180
Disease status
CR/PR/nPR 1 .013* 129
Stable/progressive 2.31 (1.32-4.05) .003 122
Missing 1.39 (.32-6.01) .66 13
Contrast
Stable/progressive versus
missing
1.67 (.48-7.00) .48
5. TRM
Main effect
RIC 1 .088* 108
MA 1.40 (.95-2.07) .088 156
6. PFS
Main effect and transplantation
year
2000 or earlier
RIC 1 24
MA .60 (.37-.97) .038 121
After 2000
RIC 1 84
MA 1.49 (.92-2.42) .102 35
Karnofsky performance status
90 1 .016* 84
<90 1.46 (1.07-1.98) .016 180
Disease status
CR/PR/nPR 1 .003* 129
Stable/progressive 1.72 (1.26-2.35) .0007 122
Missing 1.66 (.85-3.24) .14 13
Contrast
Stable/progressive versus
missing
1.04 (.54-2.00) .91
7. Neutrophil recovery
Main effect
RIC 1 .18* 129
MA 2.08 (.72-5.97) .18 160
Rai stage immediately before HCT
Early 1 .026* 159
Advanced .19 (.05-.71) .013 106
Missing .14 (.03-.72) .019 24
Contrast
Advanced versus missing 1.39 (.35-5.55) .64
* Overall P value.
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vival than the MA subjects (70% [95% CI, 56% to 82%] versus
54% [95% CI, 44% to 63%], P < .046), but no differences at 3-
and 5-year follow-up.
DISCUSSION
Our study shows that a RIC transplantation approach is
effective in subjects with relapsed CLL. Compared with MA
conditioning, RIC was associated with more rapid platelet
count recovery as well as less TRM. For transplantations
performed after 2000, RIC was also associated with
improved PFS and survival. Although the MA group was
associated with better PFS and 3-year survival for trans-
plantations performed before this time, signiﬁcantly fewer
subjects were treated than with RIC. Therefore, the patient
sample size may have limited our ability to accurately assess
for a beneﬁt with RIC. In addition, the inferior survival for RIC
transplantations in this era may also have been related to its
early phase of development.
More subjects treated with RIC HCT received prior anti-
body therapy. From this retrospective analysis, it is not
possible to determine whether this may potentially have
contributed to the improved survival outcomes compared
with MA conditioning. There were no differences between
the RIC and MA groups with regard to reported pre-
transplantation disease status or disease that was refractory
to prior therapy, including antibody-based approaches.
However, if subjects treated with RIC had received more
prior antibody therapy, it is possible that more of them
received pretransplantation therapy of greater intensity (eg,
ﬂudarabine, cyclophosphamide, and rituximab [FCR]
regimen) and had less residual disease, which were
not necessarily measured merely by comparing complete
remission rates.
Signiﬁcantly more subjects who underwent a RIC trans-
plantation received a blood graft compared with those
receiving MA regimens. However, RIC subjects did not
experience a higher incidence of acute or chronic GVHD. The
lower incidence of grade 2 to 4 acute GVHD in the RIC group
corroborates ﬁndings recently reported by the Dana Farber
Cancer Institute [13]. Because ATG was more commonly used
in our RIC subjects, this may also have inﬂuenced this result.
This agent has been shown to reduce GVHDwithout affecting
relapse and survival [23]. In addition, if more rituximab was
administered to RIC subjects before transplantation, this may
also have contributed to less acute GVHD [24].
Compared with prior smaller series [13-15], including
from single centers, the lower 5-year PFS of 30% observed
among our RIC group who underwent transplantation after
2000 may be related to heterogeneous conditioning regi-
mens with variable treatment intensity. Although for trans-
plantations performed after 2000, RIC was associated with
better PFS thanMA conditioning, this did not reach statistical
signiﬁcance in multivariate analysis, likely due to the rela-
tively small number of MA transplantations in this latter time
period. However, the better overall survival after 2000 for
the RIC groupmay be related to improved outcomes with RIC
transplantations after 2000 compared with those performed
earlier. The maximum partial likelihood method identiﬁed
this cut-off for year of HCT for the RIC group, but no such
time point was identiﬁed to distinguish outcomes for the MA
transplantations. Because this was not a randomized trial,
patient selection biases may also have inﬂuenced the out-
comes. Furthermore, in more recent years, better recognition
of poor prognostic factors before transplantation may have
Figure 2. Comparison of progression-free survival between MA and RIC allogeneic HCT for CLL. (A) Performed in 2000 or earlier. (B) Performed after 2000.
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perceived to be higher risk.
After 2000, as transplantation centers gained further
experience with RIC approaches, they also may have been
more likely to pursue such therapy rather than MA condi-
tioning. The ﬁnding of improved survival with RIC may
reﬂect a superior treatment, but it may also be related to
changes in practice over time, such as better azole antifungal
agents, enhanced recognition of pretransplantation poor
prognostic factors, or more efﬁcacious pretransplantation
cytoreduction with chemoimmunotherapy. However, a RIC
approach has also been demonstrated to induce late disease
responses for CLL [15].
Furthermore, the survival beneﬁt observed with RIC in
our study is consistent with results from Brown et al., who
reported a signiﬁcant survival advantage for RIC over MA
transplantation performed from 2004 to 2009 (83% versus
47%) [13]. The German CLL study group reported on 90
subjects from the CLL3X trial, who received RIC trans-
plantations with 6-year event-free survival and overall sur-
vival of 38% and 58%, respectively [14].
A substantial number of subjects in both the MA and RIC
groups had failed prior ﬂudarabine therapy. However, it is
not possible to differentiate relapse from true resistance,
which may affect the expected outcome. Such disease hasFigure 3. Comparison of overall survival between MA and RIC allogeneic HCbeen associated with a poor prognosis and short survival
after conventional nontransplantation therapies for CLL [25-
27]. When assessing such subjects in this study, there was no
difference in disease relapse/progression or survival between
those undergoing MA and RIC HCT. This suggests that the
unfavorable prognosis of ﬂudarabine-refractory disease may
be overcome by either MA or RIC approaches, as reported by
others [15,28].
This retrospective study was limited by differences in the
number of MA and RIC transplantations performed in both
eras in which outcomes were analyzed. There also were
insufﬁcient data for analysis regarding various poor prog-
nostic features, such as bulky lymphadenopathy (5 cm),
extent of bone marrow involvement, immunoglobulin gene
rearrangement mutational status, and chromosomal abnor-
malities. Except for bulky lymphadenopathy, investigators at
the Fred Hutchinson Cancer Research Center found no
inﬂuence of such poor prognostic factors on post-
transplantation outcomes and no correlation with graft-
versus-leukemia effects [9,15]. In addition, for CLL with a
chromosome 17p deletion, RIC allogeneic HCT has been re-
ported to achieve favorable results that may overcome the
adverse prognosis of such disease [29,30]. In the current
study, imbalances between the RIC and MA groups with re-
gard to these prognostic factors are not known. However, ifT for CLL. (A) Performed in 2000 or earlier. (B) Performed after 2000.
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ences in outcomes and this deserves further testing in the
future.
We conclude that both MA and RIC MSD transplants are
effective for advanced CLL. Pretransplantation disease status
is the most important predictor of relapse and PFS for both
forms of transplantation conditioning. Because MA trans-
plantations tended to have higher TRM and RIC trans-
plantations had more disease relapse/progression, rigorous
evaluation of pretransplantation comorbidities and disease
biology are important considerations for selection of trans-
plantation conditioning intensity.
New strategies are needed to enhance the antileukemic
effect of RIC regimens used for allogeneic HCT of CLL. From
the recently reported MA experience comparing chemo-
therapy- versus TBI-based conditioning, which included the
MA cohort of patients from the current study, there were no
differences in TRM, relapse, PFS, or survival [31]. Investiga-
tion of novel treatment agents for conditioning, as well as
adoptive cellular therapy studies and post-transplantation
maintenance therapy, may be further explored. Chimeric
antigen receptoremodiﬁed T cell infusions are one such
approach with considerable promise [32,33]. In addition,
kinase-targeted strategies have been highly active in
relapsed and refractory CLL [34,35]. Further elucidation of
the biology of immune effector cell alloreactivity against CLL
may also guide future approaches to help optimize condi-
tions for generating a graft-versus-leukemia effect in this
transplantation population.
ACKNOWLEDGMENTS
The CIBMTR is supported by Public Health Service Grant/
Cooperative Agreement U24-CA076518 from the National
Cancer Institute (NCI), the National Heart, Lung and Blood
Institute (NHLBI) and the National Institute of Allergy and
Infectious Diseases (NIAID); a Grant/Cooperative Agreement
5U10HL069294 from NHLBI and NCI; a contract
HHSH250201200016C with Health Resources and Services
Administration (HRSA/DHHS); two Grants N00014-12-1-
0142 and N00014-13-1-0039 from the Ofﬁce of Naval
Research; and grants from *Actinium Pharmaceuticals; Allos
Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the
Medical College of Wisconsin; Ariad; Be the Match Founda-
tion; *Blue Cross and Blue Shield Association; *Celgene Cor-
poration; Chimerix, Inc.; Fred Hutchinson Cancer Research
Center; Fresenius-Biotech North America, Inc.; *Gamida Cell
Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA;
Genzyme Corporation; GlaxoSmithKline; Health Research,
Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte
Corporation; Jeff Gordon Children’s Foundation; Kiadis
Pharma; The Leukemia & Lymphoma Society; Medac GmbH;
The Medical College of Wisconsin; Merck & Co, Inc.; Mil-
lennium: The Takeda Oncology Co.; *Milliman USA, Inc.;
*Miltenyi Biotec, Inc.; National Marrow Donor Program;
Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.;
Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical,
Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanoﬁ US;
Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.;
St. Baldrick’s Foundation; StemCyte, A Global Cord Blood
Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan
Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva
Neuroscience, Inc.; *THERAKOS, Inc.; University of Minne-
sota; University of Utah; and *Wellpoint, Inc. The views
expressed in this article do not reﬂect the ofﬁcial policy or
position of the National Institute of Health, the Departmentof the Navy, the Department of Defense, Health Resources
and Services Administration (HRSA) or any other agency of
the U.S. Government.
*Corporate Members.
Financial Disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.REFERENCES
1. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone
marrow transplantation in younger patients with chronic lymphocytic
leukemia. European Group for Blood and Marrow Transplantation and
the International Bone Marrow Transplant Registry. Ann Intern Med.
1996;124:311-315.
2. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow
transplantation for chronic lymphocytic leukaemia: timing of trans-
plantation and potential effect of ﬂudarabine on acute graft-versus-
host disease. Br J Haematol. 1997;97:466-473.
3. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic
stem cell transplantation for B cell chronic lymphocytic leukemia. Bone
Marrow Transplant. 2000;25:717-722.
4. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for
chronic lymphocytic leukemia: different outcome after autologous and
allogeneic transplantation and correlation with minimal residual dis-
ease status. Leukemia. 2001;15:445-451.
5. Dreger P, Montserrat E. Autologous and allogeneic stem cell trans-
plantation for chronic lymphocytic leukemia. Leukemia. 2002;16:
985-992.
6. Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor he-
matopoietic stem cell transplantation for treatment of chronic lym-
phocytic leukemia. Bone Marrow Transplant. 2002;29:817-823.
7. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow
transplantation for B-cell chronic lymphocytic leukemia after using
myeloablative conditioning: results from the Center for International
Blood and Marrow Transplant research. J Clin Oncol. 2005;23:
5788-5794.
8. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-
leukemia effect in chronic lymphocytic leukemia after reduced-
intensity conditioning and allogeneic stem-cell transplantation: the
Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:
2747-2753.
9. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell trans-
plantation after nonmyeloablative conditioning for advanced chronic
lymphocytic leukemia. J Clin Oncol. 2005;23:3819-3829.
10. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-
versus-leukemia activity after allogeneic stem cell transplantation for
chronic lymphocytic leukemia using intensity-reduced conditioning.
Leukemia. 2003;17:841-848.
11. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia
activity may overcome therapeutic resistance of chronic lymphocytic
leukemia with unmutated immunoglobulin variable heavy-chain gene
status: implications of minimal residual disease measurement with
quantitative PCR. Blood. 2004;104:2600-2602.
12. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects
after allogeneic hematopoietic cell transplantation with non-
myeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.
13. Brown JR, Kim HT, Armand P, et al. Long-term follow-up of reduced-
intensity allogeneic stem cell transplantation for chronic lymphocytic
leukemia: prognostic model to predict outcome. Leukemia. 2013;27:
362-369.
14. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and NOTCH1 muta-
tions and outcome of allotransplantation for chronic lymphocytic
leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013;
121:3284-3288.
15. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of pa-
tients with advanced chronic lymphocytic leukemia treated with
allogeneic hematopoietic cell transplantation after nonmyeloablative
conditioning. J Clin Oncol. 2008;26:4912-4920.
16. Horowitz M. The role of registries in facilitating clinical research in
BMT: examples from the Center for International Blood and Marrow
Transplant Research. Bone Marrow Transplant. 2008;42(Suppl 1):S1-S2.
17. Clark TG, Altman DG, De Stavola BL. Quantiﬁcation of the completeness
of follow-up. Lancet. 2002;359:1309-1310.
18. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for
grading acute graft-versus-host disease: retrospective comparison
with Glucksberg grade. Br J Haematol. 1997;97:855-864.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man. A long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
20. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lym-
phocytic leukemia. Blood. 1975;46:219-234.
R.M. Sobecks et al. / Biol Blood Marrow Transplant 20 (2014) 1390e1398139821. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning
regimen workshop: deﬁning the dose spectrum. Report of a workshop
convened by the center for international blood and marrow transplant
research. Biol Blood Marrow Transplant. 2009;15:367-369.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete ob-
servations. J Am Stat Assoc. 1958;53:457-481.
23. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host dis-
ease prophylaxis with or without anti-T-cell globulin in haemato-
poietic cell transplantation from matched unrelated donors: a
randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;
10:855-864.
24. Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates
with less acute graft-versus-host disease and better survival in B-cell
lymphoma patients who received allogeneic peripheral blood stem cell
transplantation. Br J Haematol. 2009;145:816-824.
25. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab
(Campath-1H) in patients who have failed ﬂudarabine: results of a
large international study. Blood. 2002;99:3554-3561.
26. Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of ﬁrst salvage
therapy for patients refractory to a ﬂudarabine regimen in chronic
lymphocytic leukemia. Leuk Lymphoma. 2002;43:1755-1762.
27. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with
ﬂudarabine, cyclophosphamide, and rituximab for relapsed and re-
fractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:
4070-4078.28. Malhotra P, Hogan WJ, Litzow MR, et al. Long-term outcome of allo-
geneic stem cell transplantation in chronic lymphocytic leukemia:
analysis after a minimum follow-up of 5 years. Leuk Lymphoma. 2008;
49:1724-1730.
29. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic
stem-cell transplantation for chronic lymphocytic leukemia with 17p
deletion: a retrospective European Group for Blood and Marrow
Transplantation analysis. J Clin Oncol. 2008;26:5094-5100.
30. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell trans-
plantation provides durable disease control in poor-risk chronic lym-
phocytic leukemia: long-term clinical and MRD results of the German
CLL Study Group CLL3X trial. Blood. 2010;116:2438-2447.
31. Sabloff M, Sobecks RM, Ahn KW, et al. Does total body irradiation
conditioning improve outcomes of myeloablative human leukocyte
antigen-identical sibling transplantations for chronic lymphocytic
leukemia? Biol Blood Marrow Transplant. 2014;20:421-424.
32. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modiﬁed
T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
33. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen re-
ceptors have potent antitumor effects and can establish memory in
patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
34. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in
relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42.
35. Wiestner A. Emerging role of kinase-targeted strategies in chronic
lymphocytic leukemia. Blood. 2012;120:4684-4691.
